Evidence map›Paper›PMID 31714427›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Reduced Time to Suppression Among Neonates With HIV Initiating Antiretroviral Therapy Within 7 Days After Birth.

Sara Domínguez-Rodríguez, Alfredo Tagarro, Paolo Palma, Caroline Foster, Thanyawee Puthanakit, Thidarat Jupimai, Nicola Cotugno, Jintanat Ananworanich, Paola Zangari, Eleni Nastouli and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 6 countries.

Sara Domínguez-RodríguezPediatric Infectious Diseases Unit, Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.
Alfredo TagarroPediatric Infectious Diseases Unit, Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.
Paolo PalmaResearch Unit in Congenital and Perinatal Infections, Division of Immunology and Infectious Diseases, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, Rome, Italy.
Caroline FosterImperial College Healthcare NHS Trust, London, United Kingdom.
Thanyawee PuthanakitDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Thidarat JupimaiDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Nicola CotugnoResearch Unit in Congenital and Perinatal Infections, Division of Immunology and Infectious Diseases, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, Rome, Italy.
Jintanat AnanworanichSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Paola ZangariResearch Unit in Congenital and Perinatal Infections, Division of Immunology and Infectious Diseases, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, Rome, Italy.
Eleni NastouliDepartment of Population, Policy and Practice, UCL GOS Institute of Child Health, London, United Kingdom.
María Ángeles Muñoz-FernándezImmuno-Molecular Laboratory, Immunology Department, Hospital General Universitario Gregorio Marañón (HGM), Instituto de Investigación Sanitaria Gregorio Marañón, CoRISpe, Spanish HIV HGM BioBank, Madrid, Spain.
María Luisa NavarroSpanish National HIV-1 Paediatric Network (CoRISPe).
Carlo GiaquintoPENTA Onlus, Padova, Italy.
Paolo RossiResearch Unit in Congenital and Perinatal Infections, Division of Immunology and Infectious Diseases, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, Rome, Italy.
Louise KuhnGertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY.
Pablo RojoPediatric Infectious Diseases Unit, Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.
Bambino Gesù Children's Hospital · ITChulalongkorn University · THHospital General Universitario Gregorio Marañón · ESUniversidad Europea de Madrid · ESImperial College Healthcare NHS Trust · GBPENTA Foundation · ITUniversity College London · GBUniversity of Amsterdam · NL

Funding

The Latent HIV Reservoir in Early-treated Thai ChildrenR01AI114236 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI PUTHANAKIT, THANYAWEE, ROBB, MERLIN L · 2014 to 2018
$2.8M
NIAID NIH HHS R01 AI114236
6 · The paper itself

Abstract

There are limited data on infants with HIV starting antiretroviral therapy (ART) in the neonatal period. We investigated the association between the timing of ART initiation and time-to-suppression among infants who tested HIV-positive and initiated ART within the first 28 days of life. The effect was estimated using cumulative probability flexible parametric spline models and a multivariable generalized additive mixed model was performed to test nonlinear associations. Forty-four neonates were included. Nineteen (43.2%) initiated ART within 7 days of life and 25 (56.8%) from 8 to 28 days. Infants treated within 7 days were 4-fold more likely to suppress earlier than those treated after 7 days [Hazard ratio (HR) 4.01 (1.7-9.5)]. For each week the ART initiation was delayed, the probability of suppression decreased by 35% (HR 0.65 [0.46-0.92]). Age at ART start was linearly associated with time-to-suppression. However, a linear association with normally distributed residuals was not found between baseline viral load and time-to-suppression, with no association found when baseline viral loads were ≤5 log(10) copies/mL, but with exponential increase in time-to-suppression with > log5 copies/mL at baseline. Starting ART within 7 days of life led to 4-fold faster time to viral suppression, in comparison to initiation from 8 to 28 days.

Indexed as

Infectious Disease Transmission, VerticalAnti-HIV AgentsCD4 Lymphocyte CountChildChild, PreschoolDrug Therapy, CombinationFemaleFollow-Up StudiesHIV InfectionsHIV Protease InhibitorsHumansInfantInfant, NewbornMaleRetrospective StudiesReverse Transcriptase InhibitorsAnti-HIV AgentsHIV Protease InhibitorsReverse Transcriptase Inhibitors

Identifiers

PMID31714427
PMCPMC6857716
OpenAlexW2988221189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.